A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137086 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Aditi A Shirke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Photochemotherapy, Prostatic Neoplasms, Photosensitizing Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Health (NIH), National Foundation of Cancer Research (NFCR).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Prostate cancer is the most prevalent cancer among men in the United States and is a leading cause of cancer-related death. Prostate specific membrane antigen (PSMA) has been established as a biomarker for prostate cancer diagnosis and treatment. This study aimed to develop a novel theranostic agent, PSMA-1-MMAE-Pc413, which integrates a PSMA-targeting ligand, the photosensitizer Pc413, and the microtubular inhibitor monomethyl auristatin E (MMAE) for synergistic therapeutic efficacy. In vitro uptake studies revealed that PSMA-1-MMAE-Pc413 demonstrated selective and specific uptake in PSMA-positive PC3pip cells but not in PSMA-negative PC3flu cells, with the uptake in PC3pip cells being approximately three times higher. In vitro cytotoxicity assays showed that, when exposed to light, PSMA-1-MMAE-Pc413 had a synergistic effect, leading to significantly greater cytotoxicity in PSMA-positive cells (IC50 = 2.2 nM) compared to PSMA-1-Pc413 with light irradiation (IC50 = 164.9 nM) or PSMA-1-MMAE-Pc413 without light irradiation (IC50 = 12.6 nM). In vivo imaging studies further demonstrated the selective uptake of PSMA-1-MMAE-Pc413 in PC3pip tumors. In in vivo studies, PSMA-1-MMAE-Pc413 dramatically improves the therapeutic outcome for prostate cancer by providing a synergistic effect that surpasses the efficacy of each treatment modality alone in PC3pip tumors. These findings suggest that PSMA-1-MMAE-Pc413 has strong potential for clinical application in improving prostate cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.
- Department of Biochemistry, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.
- Department of Radiology, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.
ORCID-Profile: Aditi A Shirke, Ethan Walker, Gopalakrishnan Ramamurthy, Abhiram Panigrahi, James P Basilion, Xinning Wang
Förderung
- NIH HHS
- National Institute of Health (NIH)
- National Foundation of Cancer Research (NFCR)
Zitieren
APA
Shirke, A. A., Walker, E., Chavali, S., Ramamurthy, G., Zhang, L., Panigrahi, A., Basilion, J. P., & Wang, X. (2024). A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137086
Vancouver
Shirke AA, Walker E, Chavali S, Ramamurthy G, Zhang L, Panigrahi A, et al. A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137086
BibTeX
@article{Shirke2024,
author = {Shirke, Aditi A and Walker, Ethan and Chavali, Sriprada and Ramamurthy, Gopalakrishnan and Zhang, Lifang and Panigrahi, Abhiram and Basilion, James P and Wang, Xinning},
title = {A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137086}
}
EUVIMED